Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00684138 · ClinicalTrials.gov registry record · Phase 4
ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)
A Phase 4 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
NCT00684138: Completed Phase 4 study, sponsored by Alcon Research.
NCT00684138 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 300 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00684138, a Phase 4 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
Study Summary
Randomized, parallel group, subject masked, multi-center six (6) month follow-up study comparing ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power IOL Model SN6AD1 implanted in both eyes to ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power IOL Model SN6AD3 implanted in both eyes.
Primary Outcome
Binocular Distance Corrected Near Visual Acuity at Best Distance (that which provides the subject with the best vision)measured in mean logMAR. logMAR is the logarithm of the minimum angle of resolution, which is a measure for visual acuity (VA). Mean logMAR is the average value of visual acuity.
Interventions
- DEVICE ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens
- DEVICE ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
What the finished NCT00684138 record still lists
NCT00684138 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens is the first listed.
NCT00684138 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00684138 about?
NCT00684138 is a clinical study titled "ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)". Randomized, parallel group, subject masked, multi-center six (6) month follow-up study comparing ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power IOL Model SN6AD1 implanted in both eyes to ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power IOL Model SN6AD3 implanted in both eyes.
What is the current status of trial NCT00684138?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2007-06. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00684138?
The interventions under investigation include: ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens (DEVICE), ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (DEVICE).
Who is sponsoring clinical trial NCT00684138?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00684138's enrollment target sits among peer trials
300 269th of 2000 higher than 1,709 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia